Abstract

The overall objective of this proposal is to coordinate and integrate the investigative activities of four New England pediatric oncology centers (Brown University/Rhode Island Hospital, Dartmouth College/Dartmouth-Hitchcock Medical Center - Norris Cotton Cancer Center, Harvard University/Massachusetts General Hospital, University of Vermont/Medical Center Hospital - Vermont Regional Cancer Center) into a single program, the New England Pediatric Oncology Consortium (NEPOC), which, through active membership in the Pediatric Oncology Group (POG), will effectively contribute to the development of a greater understanding of and more effective treatments of malignancies in children. Through formalization and efficient organization of cooperative efforts, the most effective use of the resources of each institution, in particular, the disciples of pediatric oncology, radiation medicine, pathology, and pediatric surgery, will be achieved and enable full participation and significant input into the activities of POG.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA029293-05
Application #
3557060
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1981-01-01
Project End
1986-01-31
Budget Start
1985-01-01
Budget End
1986-01-31
Support Year
5
Fiscal Year
1985
Total Cost
Indirect Cost

  Institution

Name
Rhode Island Hospital (Providence, RI)
Department
Type
DUNS #
161202122
City
Providence
State
RI
Country
United States
Zip Code

  Publications

Wacker, Pierre; Land, Vita J; Camitta, Bruce M et al. (2007) Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. J Pediatr Hematol Oncol 29:627-32
Kung, Faith H; Schwartz, Cindy L; Ferree, Carolyn R et al. (2006) POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. J Pediatr Hematol Oncol 28:362-8
Ravindranath, Y; Chang, M; Steuber, C P et al. (2005) Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19:2101-16
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Goorin, Allen M; Schwartzentruber, Douglas J; Devidas, Meenakshi et al. (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574-80
Lacayo, N J; Lum, B L; Becton, D L et al. (2002) Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia 16:920-7
Saylors 3rd, R L; Stine, K C; Sullivan, J et al. (2001) Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 19:3463-9
Mahoney Jr, D H; Cohen, M E; Friedman, H S et al. (2000) Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro Oncol 2:213-20
Land, V J; Thomas, P R; Boyett, J M et al. (1985) Comparison of maintenance treatment regimens for first central nervous system relapse in children with acute lymphocytic leukemia. A Pediatric Oncology Group study. Cancer 56:81-7